Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome
The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia, with an increase in erythrocyte mass, which predisposes to thrombotic complications. Pentoxifylline is a xanthine derivative and it is considered as a hemorrheological agent with described effects of reduction in erythrocyte and platelet aggregation, adhesion and activation of leukocytes, and endothelial damage. The main objective of this…
Conditions studied
Eisenmenger Syndrome
About this study
The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia, with an increase in erythrocyte mass, which predisposes to thrombotic complications. Pentoxifylline is a xanthine derivative and it is considered as a hemorrheological agent with described effects of reduction in erythrocyte and platelet aggregation, adhesion and activation of leukocytes, and endothelial damage. The main objective of this study is to verify if the chronic oral administration of pentoxifylline to Eisenmenger patients induces an increase in the circulating levels of thrombomodulin, a naturally occurring proteoglycan with anticoagulant, anti thrombotic and anti-inflammatory properties.
Interventions
- Drug: Pentoxifylline — Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
Primary outcomes
- Plasma concentration of Thrombomodulin (3 months and 6 months)
Eligibility information
Study locations
- Antonio Augusto Barbosa Lopes, São Paulo, Brazil
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.